Corcept Therapeutics Incorporated (NASDAQ:CORT) Position Raised by Russell Investments Group Ltd.

Russell Investments Group Ltd. increased its holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 11.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 202,504 shares of the biotechnology company's stock after acquiring an additional 21,281 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.19% of Corcept Therapeutics worth $10,204,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of CORT. Wells Fargo & Company MN increased its holdings in Corcept Therapeutics by 104.5% during the 4th quarter. Wells Fargo & Company MN now owns 90,137 shares of the biotechnology company's stock worth $4,542,000 after purchasing an additional 46,067 shares during the last quarter. Integrated Quantitative Investments LLC bought a new stake in shares of Corcept Therapeutics in the fourth quarter worth $1,088,000. Atlas Capital Advisors Inc. bought a new stake in shares of Corcept Therapeutics in the fourth quarter worth $550,000. Pitcairn Co. bought a new position in Corcept Therapeutics during the 4th quarter valued at $209,000. Finally, Trexquant Investment LP acquired a new position in Corcept Therapeutics during the 4th quarter worth $3,281,000. Institutional investors and hedge funds own 93.61% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on CORT. StockNews.com lowered shares of Corcept Therapeutics from a "buy" rating to a "hold" rating in a research note on Friday, February 28th. Truist Financial upped their price objective on Corcept Therapeutics from $76.00 to $150.00 and gave the company a "buy" rating in a research note on Monday, March 31st. HC Wainwright lifted their target price on Corcept Therapeutics from $115.00 to $150.00 and gave the stock a "buy" rating in a research report on Monday, March 31st. Piper Sandler upped their price target on Corcept Therapeutics from $128.00 to $131.00 and gave the company an "overweight" rating in a research report on Thursday, April 3rd. Finally, Canaccord Genuity Group lifted their price objective on shares of Corcept Therapeutics from $130.00 to $142.00 and gave the stock a "buy" rating in a report on Tuesday, April 1st. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $143.25.

Remove Ads

Corcept Therapeutics Stock Performance

Shares of NASDAQ:CORT traded down $4.97 during trading on Wednesday, hitting $64.62. 1,165,942 shares of the company traded hands, compared to its average volume of 1,125,947. The company has a quick ratio of 3.64, a current ratio of 3.70 and a debt-to-equity ratio of 0.01. The business's fifty day moving average is $65.73 and its 200-day moving average is $58.04. The stock has a market capitalization of $6.82 billion, a price-to-earnings ratio of 51.29 and a beta of 0.15. Corcept Therapeutics Incorporated has a one year low of $20.84 and a one year high of $117.33.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $0.26 EPS for the quarter, missing analysts' consensus estimates of $0.37 by ($0.11). The company had revenue of $181.89 million for the quarter, compared to the consensus estimate of $200.12 million. Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. As a group, equities analysts predict that Corcept Therapeutics Incorporated will post 1.36 earnings per share for the current fiscal year.

Insider Transactions at Corcept Therapeutics

In related news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the stock in a transaction that occurred on Thursday, April 10th. The stock was sold at an average price of $70.22, for a total value of $154,484.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Sean Maduck sold 18,303 shares of Corcept Therapeutics stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $60.69, for a total value of $1,110,809.07. Following the sale, the insider now directly owns 85,622 shares in the company, valued at $5,196,399.18. The trade was a 17.61 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 163,124 shares of company stock worth $15,117,614. Insiders own 20.50% of the company's stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.